We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Albemarle (ALB - Free Report) closed at $181.39 in the latest trading session, marking a +2.45% move from the prior day. This change outpaced the S&P 500's 0.54% gain on the day. At the same time, the Dow added 0.66%, and the tech-heavy Nasdaq gained 0.77%.
The stock of specialty chemicals company has fallen by 5.23% in the past month, leading the Basic Materials sector's loss of 14.52% and undershooting the S&P 500's loss of 4.71%.
Market participants will be closely following the financial results of Albemarle in its upcoming release. The company's earnings per share (EPS) are projected to be $0.78, reflecting a 533.33% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.28 billion, showing a 18.91% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.15 per share and a revenue of $5.58 billion, signifying shifts of +1131.65% and +8.48%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Albemarle. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 21.51% higher. Currently, Albemarle is carrying a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Albemarle is presently being traded at a Forward P/E ratio of 21.73. For comparison, its industry has an average Forward P/E of 18.27, which means Albemarle is trading at a premium to the group.
It's also important to note that ALB currently trades at a PEG ratio of 1.36. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Chemical - Diversified was holding an average PEG ratio of 1.51 at yesterday's closing price.
The Chemical - Diversified industry is part of the Basic Materials sector. At present, this industry carries a Zacks Industry Rank of 200, placing it within the bottom 19% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Outpaces Stock Market Gains: What You Should Know
Albemarle (ALB - Free Report) closed at $181.39 in the latest trading session, marking a +2.45% move from the prior day. This change outpaced the S&P 500's 0.54% gain on the day. At the same time, the Dow added 0.66%, and the tech-heavy Nasdaq gained 0.77%.
The stock of specialty chemicals company has fallen by 5.23% in the past month, leading the Basic Materials sector's loss of 14.52% and undershooting the S&P 500's loss of 4.71%.
Market participants will be closely following the financial results of Albemarle in its upcoming release. The company's earnings per share (EPS) are projected to be $0.78, reflecting a 533.33% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.28 billion, showing a 18.91% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.15 per share and a revenue of $5.58 billion, signifying shifts of +1131.65% and +8.48%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Albemarle. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 21.51% higher. Currently, Albemarle is carrying a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Albemarle is presently being traded at a Forward P/E ratio of 21.73. For comparison, its industry has an average Forward P/E of 18.27, which means Albemarle is trading at a premium to the group.
It's also important to note that ALB currently trades at a PEG ratio of 1.36. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Chemical - Diversified was holding an average PEG ratio of 1.51 at yesterday's closing price.
The Chemical - Diversified industry is part of the Basic Materials sector. At present, this industry carries a Zacks Industry Rank of 200, placing it within the bottom 19% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.